lisdexamfetamine (Vyvanse)
Jump to navigation
Jump to search
Introduction
dextroamphetamine bound to lysine (lisdexamfetamine mesylate) DEA class 2
Indications
- attention deficit hyperactivity disorder (ADHD)
- binge eating disorder
- narcolepsy[2] (not FDA-approved use)
- augmentation of SSRI for depression somewhat effective[4]
Dosage
30-70 mg QD
Pharmacokinetics
More general terms
References
- ↑ Prescriber's Letter 14(5): 2007 New Drug: Vyvanse (Lisdexamfetamine Dimesylate) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230507&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Deprecated Reference
- ↑ FDA News Release. January 30, 2015 FDA expands uses of Vyvanse to treat binge-eating disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432543.htm
- ↑ 4.0 4.1 4.2 Giacobbe P, Rakita U, Lam R et al Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. J Affect Disord. 2017 Oct 3;226:294-300. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/29028590
- ↑ Vyvanse Prescribing Information http://pi.shirecontent.com/PI/PDFs/Vyvanse_USA_ENG.pdf